Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …
Sickle cell disease (SCD) is a pathology caused by a mutative hemoglobin protein that produces rigid, sickle-shaped red blood cells (RBCs). Lifelong complications of SCD include acute veno-occlusive crises (VOCs), whose recurrence takes a significant toll on patients, and end-organ …
Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the intrahepatic bile ducts that is often misdiagnosed until it progresses to advanced stages, including end-stage liver disease. Symptoms such as intractable pruritus and severe fatigue, often accompanied by abnormal …
Biomarker and molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and in underserved communities. At present, patients with cancer in racially or ethnicly underserved communities are not receiving …
Crohn’s disease (CD) can cause progressive bowel damage, impaired quality of life, and permanent disability. Severity and presentation can vary widely from person to person, necessitating an individualized treatment approach. The use of more readily available imaging modalities such as …
Ulcerative colitis (UC) affects around three million people in the United States. Delays in treatment coverage approval, costs of managing the disease, and uncertainties around new treatment options significantly impact how well patients react to treatment, and short- and long-term …
Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from …
Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mABs) neutralize …
Studies demonstrate that approximately 65%-82% of patients with Crohn’s disease (CD) report at least some degree of bowel urgency, but this symptom is largely underrecognized by gastroenterologists and health care professionals (HCPs) caring for patients with inflammatory bowel disease (IBD). …